High ApoB, CAC Zero: What Your Heart Tests Are Really Saying
In a Nutshell
Atherosclerosis is caused by ApoB particles penetrating arterial walls, with risk determined by particle count × time exposed rather than cholesterol cargo alone; high Lp(a) and CAC scores each independently predict events, with their combination carrying the highest risk. When ApoB and LDL-C disagree, ApoB wins as the better predictor, and even lean, metabolically healthy people with high ApoB on keto diets have not proven immunity from plaque. The goal is preventing heart attacks and strokes through lowering ApoB particles, optimizing metabolic health and blood pressure, and using imaging and Lp(a) testing to guide decisions—not chasing lab numbers in isolation.
These notes were generated by AI and may contain inaccuracies.
Two people, confident, smart, quoting science, but they can't both be right. One says, "Lower your ApoB as far as humanly possible, because that's what causes heart attacks." The second one says, "If your insulin is good, triglycerides are low, and your blood pressure is fine, your lipid panel doesn't matter." The loudest voices online have left people more confused than ever. This isn't a fight about the science. This is a fight related to oversimplification, related to social media communication. Each side is holding one piece of a puzzle and calling it the whole picture. By the end of the video, the arguments around ApoB, CAC, ApoE4, and whether plaque can even reverse, they're going to start sounding like people pointing at different parts of that proverbial elephant.
This is not a theoretical argument. The speaker's father had a transplant, their grandfather died of a stroke. They have been healthy their whole life, careful their whole life, and their own ApoB came back high anyways. If you already know the terms ApoB, Lp(a), CAC, advanced panels, this is how to read them when they disagree. If this is the first time you've ever heard those words, this is made for you, because the whole story is built from the ground up, one layer at a time. The goal is to make you the sharpest person in the room at your next doctor's visit.
Forget the picture where cholesterol is grease, the arteries are pipes, and the grease slowly clogs the pipe like a kitchen drain. That picture is wrong, incomplete, and almost every bad argument online is built on that metaphor. The artery is not a pipe. It is a living road inside a living city. The road carries traffic. The road has a surface that can get worn down. And underneath that surface is a wall. The city has weather. It has repair crews and like every city, it has one disaster it is quietly organized around preventing.
The traffic is all the apoB containing particles. LDL particles, VLDL remnants, the IDL, the Lp(a). These are vehicles moving cargo through the blood. ApoB itself is not a vehicle. ApoB is a license plate. Almost every one of these vehicles carries exactly one apoB tag, which is why if you ever want to know how heavy the traffic is, you count license plates. The big truck and a little motorcycle carry widely different amounts of cargo or cholesterol in this case, but each one gets one license plate. So, the plate count, apoB, is the truest traffic count.
Cholesterol or on the lab panel, seen as LDL cholesterol or LDLC or HDLC, which is the so-called good cholesterol. LDLC isn't the traffic, it's the cargo. That's how much cholesterol is riding inside each of those LDL vehicles. Combined together, that's the LDLC on the lab panel. You can have the same total cargo carried by a very few big trucks or by a swarm of many smart cars. This matters later because we're going to talk about traffic accidents.
The wall or inside the road is actually where the disease lives. Blood pressure is force. Every heartbeat is the road taking a hit. Run that force high for years and it's like driving heavy trucks over the same surface in the rain every second for decades. And when there are turns in the road, they're sharp, for example, you run into a higher chance of accidents, the faster you're driving or the higher the force. It's similar between traffic and what's going on in the blood vessels.
Metabolic health is the road condition and also the repair crew. It's basically stuff that affects the health of the road. Glucose, insulin resistance, triglycerides, visceral fat, sleep apnea, kidney function, smoking, inflammation. This all determines whether the city is well maintained or quietly just falling apart.
Lp(a) is a special type of traffic. It's a vehicle inherited, and unfortunately, it's got little spikes on its tires, so it's going to hurt the road a bit more as it's driving. The most common gene talked about is ApoE with relevance to atherosclerosis. That and the rest of family history, they're not diseases itself, they're like intelligence reports. They signal what is more likely to happen, where the damage is supposed to be happening, and tells you essentially what neighborhoods to inspect and how early, if using that traffic metaphor.
Imaging is a surveillance system. CAC, CCTA, CIN, stress tests, AI plaque analysis. Every single kind of test is like a camera pointing at a different street, and they all answer different questions. It's like having a night vision mode camera, an infrared mode camera, a regular vision camera, CCTV, audio only. They're all quite different.
The disaster, the thing this entire city is organized around preventing, is not just random numbers on a lab report. Those are just clues, actually. It is a clot, a blockage, blood that suddenly cannot reach the heart or the brain, and therefore leads to that heart attack or stroke.
The disease does not begin in the middle of the lumen or the center of that blood vessel or the open road. It actually begins inside the wall, or in this case, in the analogy, it's what's happening underneath the surface of the road. If cut that road in cross-section, imagine that the top layer is the open channel where blood touches the surface of that road or the lumen, the endothelium. Then, right under the endothelium is something called the intima, which is the inner layer of the blood vessel wall. Plaque doesn't start with just regular traffic. It happens when the LDL gets stuck, crosses that endothelial layer, and is wedged, essentially, underneath. Why do they get wedged? There are these scaffolding molecules in there, proteoglycans, that grab particles, kind of like burrs catching in carpet. And then, once a particle gets stuck where it should not be, the whole city treats it like a problem. As it's stuck there, it oxidizes, and then the immune system can detect it and flags it for clean up. This chemical calls as come here and the immune cells called monocytes stick to the surface, crawl into the wall, turn into macrophages. The macrophages eat the trapped particles and when they get stuffed full of fat, they become something with one of the best names. They become foam cells and they look just like foam under a microscope.
When that occurs, the repair instinct kicks in further. So, smooth muscle cells literally move in and they lay down collagen to create this fibrous cap over the mess. Kind of like the city repair people trying to pave over this pothole, this damaged road. Later on, calcium will show up to harden as the repair ages. So, it becomes this like tough scar. This part is really beautiful, not just frightening because it's about the body trying to do repair. The body is really trying to help. But, run that repair cycle for years, decade after decade and that repair, that scar becomes a problem. Like when you try to fix a street over and over again just by patching it, patching it, it doesn't hold forever. It becomes this worse problem. It collapses.
Half of heart attacks occur in people who have perfectly normal lipid panels. It's because a heart attack has nothing to do with numbers on the lab report. It's actually an event, in a moment when the plaque, so remember all that healing scar, it ruptures. So, it breaks off or maybe it erodes just enough so that the inside of it is exposed to the blood coming on by. So, what happens is blood has all this material that detects wounds and the blood's job is to create scabs. Just like when you get a paper cut or some other kind of open wound, the blood is going to clot to try and heal it. The problem is when a clot happens on the inside of the blood layer, there's not enough room for that clot and it can cut off circulation. It cuts off the oxygen giving blood going to an important organ. And in this case that we're talking about, it causes a heart attack or it causes a stroke if it's blocking off oxygen to the brain.
When someone asks, "Is apoB the cause? Is it inflammation? Is it the clot itself? Is it metabolic health?" The answer is not so simple. All this traffic creates the exposure, the road quality decides what gets retained, force, road conditions, weather shape the damage and the repair. And eventually, if everything goes awry, it causes that accident.
If this is so dangerous, it's the number one killer in the world, why would evolution allow this to continue? It's really hard to answer questions about evolution, honestly, but there have been studies in mummies. So, we have found atherosclerosis in people who died thousands of years ago. So, in 2013, a study was published in The Lancet where the researchers took CT scanners to 137 mummies. These are ancient Egyptians, Peruvians, ancestral Pueblo Indians, hunter-gatherers from the Aleutian Islands. These are people separated by oceans and thousands of years. They've eaten completely different diets and lived completely different lifestyles. And about a third of them had probable or definite atherosclerosis. That's pretty strange, right? Because the internet's going to tell you that it's all about modern lifestyle, these villains, sugar, or seed oils, or whatever is trending this week that explains heart disease, all causes of death. But, as we've seen in these studies, this is far older than agriculture.
Why do we still have it? It turns out that the machinery that builds the trap is the same machinery that keeps you alive. Lipoproteins exist because cholesterol and fat cannot dissolve in blood. So, if you've ever tried to mix oil and water, you'll know that they will not mix. That's the same thing for the cholesterol and fat. They have to have a way to get transported in the blood. You have to move them from place to place in order to survive. Cholesterol is necessary for every single cell membrane you have in the body. We've got a lot of cell membranes. And you need it to build hormones, as well. You need fat for energy delivery. Macrophages exist to clean up damage. And clotting exists so a paper cut doesn't kill you. Smooth muscle and collagen exists to wall off injury. Every single character in that heart attack story has a day job that's keeping you alive right now. So, the problem was never the tool. The problem is the place, dose, time, and lifespan. Arteries live under higher pressure than veins. Pulsing flow, turbulence at every branch, constant wall stress. Drop that same useful machinery into a high pressure environment, run it for decades, and the helper becomes the hazard. Long story short, we've just come to live too long. Evolution was not solving for clean arteries at 85. It was solving for surviving long enough to have children, and everything after that it left to us.
The mummies do not let anyone off the hook. They do not prove that ancient people had our risk. And the CT mostly sees calcified plaque. So, it misses a ton of the other disease, the soft plaque. They're not a permission to ignore our lifestyle, just say, "Well, there's nothing we could do about it." Even the mummies have atherosclerosis. Instead, the lesson here is that we've had this vulnerability since the ancient times. It's not just something that has to do with modern life. It just put the old biology into this longer, higher pressure experiment than it was ever designed to survive. Yes, we've gotten more years of life than ever. That means more to years of traffic, more hypertension, more insulin resistance, more kidney disease, sleep apnea, visceral fat. More time for a slow disease to finish what it started. So, why does atherosclerosis still exist? It's because useful biology becomes dangerous in the wrong place at the wrong dose over enough time.
The longer the panel, the more it tempts you to believe the smallest, weirdest number is holding some sort of deep truth. It usually isn't. Every single number on a panel is answering one of four questions. Is this about the license plates, the apoB, the cargo or cholesterol, the vehicle size, or a special risk vehicle?
ApoB is the number of license plates. That's the structural protein on every single atherogenic particle. LDL, the VLDL remnants, the IDL, the Lp(a). So, these all look like different blobs if you were to really zoom in and look at them, and we have to classify them through chemical means. And one way is by finding this tag. So, apoB is the closest thing you have to an honest count of how many dangerous vehicles there are in your blood vessels.
Then we've got the particle. So, LDL-P and whatever P, something with a P, that just means particle. These are counts as well, and they're reported by tests like the NMR where other advanced lipid panels, and they are labeling how many of the vehicles of each type. So, LDL-P is the number of particles of LDL, and HDL-P is the number of particles of HDL, and so forth. So, this is useful. It's more narrow than the apoB. It typically finds that it confuses the picture for most people more than necessary. Just focus on the apoB, and also the Lp(a) just because it's a special risk particle.
Then we've got LDL-C or something C. So, that refers to the cholesterol. That's the cargo. So, that's how much cholesterol is riding inside the LDL particles. It doesn't tell you how many particles are carrying it. And then, if you see something called the non-HDL-C, that's the broader cargo. So, LDL-C plus all the total cholesterol basically, in particles that are not HDL. It is very confusing, but it's mentioned here because it's going to be on the lipid panel. It's not super useful a category, and it comes from legacy understanding of what is important to count.
The first trap you don't want to fall into is confusing your cargo with the count. So, say two people walk in with the exact same LDL-C. One of them carries that cholesterol, that cargo, in a few fully loaded trucks. That means they've got a lower LDL-P, fewer particles. Then the other carries the same amount of cholesterol in a swarm of small, half-empty cars, or even motorbikes. That's many more particles. So, if you imagine a road, what's going to cause more accidents? One big truck or 100 motorbikes, even if they're all carrying, combined, the same amount, the one truck and the 100 motorbikes? Of course, 100 motorbikes. They're just running around causing chaos. They're hitting the road with many more times and potentially bouncing off each other, causing a lot of potential accidents. Same thing with our cholesterol. Same cargo number, completely different traffic. And remember what actually causes the disease. That wall of the blood vessel doesn't get exposed to the cholesterol total. It only gets hit by the particles, one at a time, over and over. So, we doctors call that discordance. When the particle number, like an apoB or LDL-P, is very different from the LDL-C, then we know something's up. And when there is a discordance like this, the count is usually what we care about. That's what tells the truth about your risk. The evidence supports this. In the Framingham Offspring Study, the particle count predicted future events better than the cholesterol number. And in the 2025 discordance literature, when apoB and LDL-C disagree, apoB just keeps winning. One 2025 review makes this particularly distinct. So, apoB beat LDL-C in all nine discordance comparisons that were run, and they also beat non-HDL-C in seven of the nine. Doesn't mean that LDL-C is useless. It is, for better or worse, embedded in all the guidelines, and that's basically what we use in a lot of primary care offices. And a lot of trials were run using LDL-C as a biomarker to track. So, for what it's worth, for legacy reasons, it matters, but if you're really looking at your real risk, the particle count or the ApoB is the much more useful number.
When it comes to particle size, small dense is usually worse than big fluffy. Usually, when you see a lot of small dense LDL, or that number is high, it correlates with insulin resistance, higher triglycerides, lower HDL, fatty liver, visceral fat. It's a metabolic fingerprint, essentially. And these smaller particles behave worse for a lot of plausible reasons. So, they are cholesterol-depleted, they hang around in more inflammatory environment, and you need more of them to carry the same cargo. So, if a lot of small dense LDL is seen on someone's panel, it shouldn't be ignored, but it's also just another clue. If that is seen, ask, why is this happening? Is it because of some insulin resistance going on, high triglycerides, diabetes, fatty liver? Is it a remnant problem? It's a pattern pointing at something about the road conditions. That might make you think. So, this next part is maybe very confusing, because if we said small dense is harmful, you might think large buoyant fluffy LDL is harmless. But, a large LDL particle is still an LDL particle. If your ApoB is high, your count is high. Big particles don't get a free pass through the wall. A clean-looking pattern is still not the same as a safe one. So, when people come telling, "Oh, I've got this great pattern of size on my particle part of my advanced lipid panel." The response is, "Okay, that's good. That's better than a bad pattern, certainly, but it's not more important than looking at the total number of particles."
VLDL remnants are like a delivery truck on its way back to the depot. It dropped off some of its triglyceride cargo, so it's smaller now or lighter now, but it still carries that same apoB tag, and it still can lodge in the wall. So, remnants matter most when triglycerides are high, when remnant cholesterol is high, and when the metabolic picture is messy.
Lp(a) is a special risk factor, a special vehicle. And most people never think about it because we used to not test for it ever, basically. Now, it's gotten a lot more popular. It is because the pharma companies are about to come out with some great drugs that will treat high Lp(a). So, they are telling everyone, "Please test for Lp(a) so you know if you are one of our future customers." But, the good part is this is an important thing to tackle. We do want Lp(a) to go down as much as we can because it is a risky particle, and unfortunately, it doesn't go down very much with lifestyle or any of our current drugs. They can help, but we do need some of these new drugs to really tackle it. So, structurally, Lp(a) looks like an LDL particle, but it has this little extra tail bolted on. It's called lowercase apo(a), and that tail changes everything. So, Lp(a) still creates ordinary particle exposure, so it still counts. Like, one Lp(a) particle is still one apoB, but it's not just LDL with a costume, a special costume. It actually contains something called oxidized phospholipids, and that will actually drive inflammation and calcification much more than your typical LDL particle. That little apo little a tail looks chemically like something called plasminogen, which is a protein involved in dissolving clots, which links that Lp(a) to the clotting side of the story that we were talking about. It shouldn't be oversimplified to say this makes clots, but Lp(a) is indeed a special vehicle that can take part in both the atherosclerosis part, that plaque part, as well as the inflammation part, the calcification part, and even aortic valve disease. It really deserves its own line on its lab. A lot of people are just going to say you can just get the apo B and that's it, but it is argued you should get your Lp(a) at least one time in your life. Since it is genetically determined, if it's high once, it's always going to be high unless you get on some medications. A 2024 genetic analysis compared Lp(a) and LDL particle for particle. It used the same trick we have been using this whole episode. Every single one carries a single apo B tag, so you can line them up one to one, and the estimate was very striking. Per particle, Lp(a) looked about six times more atherogenic than LDL for coronary heart disease. Don't turn that into a personal risk calculator, it's not that precise. This is based on population genetics, and it's not meant to be a prediction about you, but it does tell you just how high risk having Lp(a) is. So, especially if you have a strong family history of heart disease, especially early onset heart disease, familial hypercholesterolemia, calcific aortic valve disease, or risk that just doesn't add up, make sure that you get Lp(a) tested. And if you happen to have a high Lp(a), you'll probably want to tell your relatives, especially your first degree relatives. It's inherited, so it's come from one of your parents at least, and all of your siblings or children likely have this risk, too. In phase two trials, drugs like lipodiscerin and muvalaplin have produced large reductions in Lp(a), so there is hope right around the corner for all of you that have Lp(a). And that's actually far more people than most realize.
Before anyone asks about niacin, because someone always does, niacin can lower Lp(a) a little, but that is not enough. Aim high and HPS2 Thrive are studies that demonstrate why niacin is not reached for. Moving the number is not the same as preventing the eventual heart attack. And also, high-dose niacin brings side effects without clear added benefit on top of statins. Hold that thought, we're going to get see this pattern again and again, where just changing a number is not the same as changing the outcome. But if you have a high Lp(a), it's not a dead end. It does tell you to get serious about every risk you can actually move, though, and it tells you to to screen your family, because your first degree relatives may carry the same high number and not know it. Now, can you actually lower your Lp(a)? That's where it gets frustrating, because most of our usual lipid drugs barely touch Lp(a), and one of them actually makes it go up. So, statins, our workhorse for lowering apoB, unfortunately doesn't lower Lp(a). If anything, some studies show it nudges it up a little bit, about 10%. That surprises people, but is not a reason to stop a statin you
PCSK9 inhibitors like Repatha lower Lp(a) 20 to 25% as a side effect of particle clearance. Niacin lowers Lp(a) modestly, but the AIM-HIGH and HPS2-THRIVE studies showed that moving the number with niacin does not equal lowering heart attack risk. High-dose niacin also brings significant side effects without clear added benefit.
A new class of RNA-based therapies including pelacarsen, olpasiran, and lipodisiran, plus the oral drug muvalaplin, can lower Lp(a) by 80 to over 90% in trials. Outcome trials determining whether this level of Lp(a) reduction prevents heart attacks and strokes have not yet been reported.
A lean, metabolically healthy person on low-carb or keto diets with perfect blood pressure, A1C, triglycerides, HDL, and inflammation often sees LDL-C, LDL-P, and ApoB rise significantly. The question becomes whether this matters given their otherwise optimal metabolic profile.
High ApoB represents a traffic problem while excellent metabolic health represents perfect road conditions. One does not cancel the other. Great road conditions reduce accident likelihood but do not eliminate the traffic entirely. Particles can still cause problems and become trapped in vessel walls. Complete prevention requires both low particle burden and optimal road conditions, with timing, dose, age, and inherited risk all playing roles.
A 2017 European Atherosclerosis Society study analyzing genetics, population studies, and trials in over 2 million people concluded that particle damage is both causal and cumulative. The relevant metric is not just how high ApoB runs, but how high multiplied by how long, analogous to pack years for smoking.
A 2024 cross-sectional CCTA study of lean, metabolically healthy people on carb-restricted diets with LDL-C of at least 190 found no higher plaque burden than matched controls after an average of 4.7 years on the diet. The study is limited by its cross-sectional nature, single snapshot timing, lack of randomization, and imaging rather than event data.
A longitudinal paper often cited with the headline "plaque predicts plaque, ApoB does not" was retracted this year due to methodology problems too significant to fix.
The SPRINT trial from 2015 with over 9,000 higher-risk adults without diabetes or prior stroke found that targeting systolic blood pressure below 120 rather than below 140 reduced major cardiovascular events by 25% and all-cause mortality by 27%. However, intensive lowering caused more adverse events, particularly in frail individuals.
Road conditions include insulin resistance, diabetes, visceral fat, fatty liver, kidney disease, sleep apnea, smoking, autoimmune disease, and menopause transition in women. These factors explain how individuals can have normal LDL-C or ApoB yet still develop plaque.
hs-CRP serves as a marker of inflammatory signaling, particularly through IL-6 pathways, rather than a direct cause. The CANTOS trial with over 10,000 post-heart attack patients with high CRP demonstrated that canakinumab reduced future events by 15% without affecting LDL-C. COLCOT and LoDoCo2 studies brought low-dose colchicine into consideration for coronary disease patients, while CIRT found that low-dose methotrexate did not reduce heart attack or stroke events.
ApoE4 carriers face roughly 20% higher coronary risk with one copy and 40-45% higher risk with two copies compared to E3/E3 genotype, based on a 2007 JAMA meta-analysis. The gene codes for a protein involved in lipid particle clearance and remnant removal through liver receptors.
Family history provides real-world evidence that often supersedes genetic testing alone. Patterns of early heart disease, stroke, sudden cardiac death, or unexplained vascular disease in parents or siblings warrant earlier and more aggressive evaluation.
CAC measures calcified coronary plaque and is inexpensive (under $100) but can falsely reassure those with high lifetime risk who have not yet calcified plaque. CCTA provides direct anatomical visualization including soft plaque, stenosis, and plaque composition. The SCOTT HEART trial showed that adding CCTA to standard care in 4,000 patients with stable chest pain reduced heart attacks and coronary deaths by 40% over 5 years.
AI quantitative plaque analysis on CCTA provides more consistent measurement than human visual assessment. Modern CT protocols deliver less radiation than mammography.
Stress testing evaluates whether flow becomes limited under demand but does not detect plaque presence. CIMT has variable methodology and adds limited predictive value, though carotid plaque presence indicates systemic disease.
A high Lp(a) with CAC of zero is not a contradiction but reflects two different measurements. CAC of zero indicates no calcified coronary plaque today, while Lp(a) represents inherited high-risk particle burden. The higher-risk factor takes precedence in decision-making.
A 2022 analysis found that LP(a) and CAC each predict events independently, but people with both high LP(a) and elevated CAC carry the highest risk. A 2026 multi-cohort study of over 11,000 people followed for 15 years showed that CAC still stratifies risk even when LP(a) is elevated. Having a zero CAC score remains protective even with high LP(a).
When facing high LP(a) without available drugs, the strategy is to aggressively lower all other modifiable risks: intensify apoB and LDL reduction, treat blood pressure, avoid smoking, manage diabetes and insulin resistance, address kidney disease, sleep apnea, and inflammatory conditions, and screen family members. Imaging should be used based on age, symptoms, family history, or other risk factors.
Reversal can mean different things: plaque volume reduction, soft plaque stabilization, denser scar formation, or fewer clinical events. These are distinct outcomes. Calcified plaque does not melt away. Reports of CAC scores decreasing usually reflect test margin of error rather than true regression. Serial CAC scanning is a poor tool for judging treatment success because the score weights calcium density, and plaque calcification represents stabilization rather than progression.
CT coronary angiography provides the clearest visualization of plaque regression. The strongest evidence for plaque shrinkage and stabilization comes from intensive LDL and apoB lowering with medications including statins, ezetimibe, and PCSK9 inhibitors. The GLAGOV trial demonstrated plaque volume reduction on ultrasound with these treatments. The PAC AMI trial showed that adding PCSK9 inhibitors after heart attack resulted in smaller, more stable plaques with thicker caps and smaller lipid cores.
Other therapies with event-reduction evidence in appropriate contexts include icosapent ethyl for high-triglyceride patients, colchicine for selected secondary prevention cases, and foundational interventions: blood pressure control, smoking cessation, diabetes treatment, exercise, sleep apnea management, body composition optimization, and kidney health maintenance.
The ESSENCE TIMI 73B trial tested olanzapine, which dramatically lowered triglycerides and remnant cholesterol but showed no significant reduction in non-calcified plaque volume after 12 months. This illustrates that lab improvements, imaging changes, and clinical event reduction represent three separate proof points. Changing one does not guarantee the next. The ultimate goal remains preventing heart attacks and strokes, not achieving favorable imaging.
Medications function as tools with extensive cardiovascular outcome data. Statins lower atherogenic particle traffic by inhibiting liver cholesterol synthesis, upregulating LDL receptors, and providing plaque-stabilizing and anti-inflammatory effects. Muscle symptoms occur but are frequently not caused by the statin itself. The SAMSON trial demonstrated that symptoms were equivalent between statin and placebo months, both significantly higher than no-pill months, indicating nocebo effects and other contributing factors.
Serious statin-induced muscle injury occurs in under 0.1% of users. Serious liver toxicity affects approximately 0.001%. New diabetes diagnoses increase moderately, particularly at higher doses and in pre-diabetic individuals. A 2024 individual participant meta-analysis confirmed this risk is dose-related and concentrated in those with elevated baseline blood sugar. Cognitive concerns lack support from randomized data; the Ebbinghaus extension showed no neurocognitive signals even with median LDL-C around 35 mg/dL.
CAC scores may rise during statin treatment as plaque shifts toward denser, more stable calcification. This does not indicate worsening disease. Serial CAC remains an inappropriate metric for assessing statin efficacy.
Ezetimibe blocks intestinal cholesterol absorption via NPC1L1 transporter inhibition. The IMPROVE-IT trial demonstrated event reduction post-heart attack when added to statins.
PCSK9 inhibitors (evolocumab, alirocumab) preserve LDL receptors by blocking their degradation. FOURIER and ODYSSEY OUTCOMES trials showed 15% event reduction on top of statins, with alirocumab also reducing mortality. Inclisiran uses siRNA technology with twice-yearly dosing but lacks completed cardiovascular outcome data.
Bempedoic acid inhibits ATP citrate lyase upstream in cholesterol synthesis. The CLEAR Outcomes trial demonstrated event reduction in statin-intolerant patients, though with increased uric acid, gout, gallstones, and tendinopathy risks.
This dialysis-like procedure physically removes apoB particles including LP(a), achieving 60% reductions per session. It remains the only FDA-approved treatment for severe LP(a) elevation in familial hypercholesterolemia with established disease. The PRO(a)LiFe study showed sharp event rate reductions. Treatment requires weekly or biweekly sessions lasting hours, representing a significant lifestyle burden and last-resort option.
Blood pressure medications and exercise reduce mechanical stress on arterial walls. Exercise provides substantial blood pressure benefits and endothelial health improvements relevant to both cardiovascular and neurovascular disease prevention.
This purified EPA preparation reduced cardiovascular events in high-risk, high-triglyceride patients on statins in the REDUCE-IT trial. Results do not extend to generic fish oil supplements, and triglyceride reduction alone does not reverse plaque.
Low-dose colchicine reduces inflammatory signaling through neutrophil and inflammasome pathways without affecting apoB or LDL-C. The CLOC and LoDoCo 2 trials demonstrated event reduction in stable coronary disease patients. It belongs in secondary prevention for established disease rather than primary prevention based solely on elevated hsCRP. Side effects include gastrointestinal symptoms, kidney and liver considerations, drug interactions, and rare bone marrow suppression.
These agents address clot formation rather than plaque biology and prove life-saving in secondary prevention or atrial fibrillation. Bleeding risk precludes routine primary prevention use, consistent with aspirin recommendations shifting away from universal application.
Brain cholesterol synthesis occurs independently behind the blood-brain barrier. The FOURIER OLE trial found LDL-C below 20 mg/dL associated with lower cardiovascular risk without safety signals for hemorrhagic stroke, neurocognitive events, diabetes, cataracts, cancer, muscle events, or non-cardiovascular death. Ebbinghaus extension data confirmed no cognitive harm at median LDL-C around 35 mg/dL.
Valid supplement assessment requires: biologically plausible mechanism, demonstrated biomarker changes, imaging or structural improvements, and ultimately clinical outcome reduction. Most supplements reach only the mechanism stage without outcome evidence.
Nattokinase showed no meaningful effect on carotid thickness or stiffness in a 2021 double-blind trial of 265 low-risk adults over 3 years despite fibrinolytic mechanism. Vitamin K2 has plausible calcification biology with mixed human data. Berberine modestly improves LDL-C, triglycerides, apoB, and glucose markers without proven plaque regression or event reduction.
Red yeast rice contains monacolin K, chemically identical to lovastatin, carrying equivalent interactions, pregnancy concerns, plus supplement risks of variable dosing, quality inconsistency, and contamination. High-dose vitamin C lacks outcome evidence for plaque reversal despite mechanistic interest regarding LP(a).
Atherosclerosis assessment requires asking: Does this factor add traffic (apoB particles), force (blood pressure), worsen road conditions (inflammation, repair capacity), or provide actionable intelligence for earlier intervention? The critical question remains whether intervention prevents heart attack or stroke rather than merely altering anxiety levels or intermediate markers.
Keep Hillary Lin, MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
